Fellowship · Miami, FL
Sponsored by University of Miami/Jackson Health System
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
The New England journal of medicine · 2022 · 755 citations · Michael Benatar
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.
Neurology · 2021 · 575 citations · Michael Benatar
Antiseizure Medications for Adults With Epilepsy: A Review.
JAMA · 2022 · 353 citations · Andres Kanner
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
The Lancet. Neurology · 2023 · 236 citations · Volkan Granit, Michael Benatar, Adam Slansky
Psychiatric Comorbidities in Persons With Epilepsy Compared With Persons Without Epilepsy: A Systematic Review and Meta-Analysis.
JAMA neurology · 2025 · 53 citations · Andres Kanner
Psychiatric Comorbidities in People With Epilepsy.
Neurology. Clinical practice · 2021 · 186 citations ·
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
The New England journal of medicine · 2025 · 51 citations · Michael Benatar
Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease prevention.
The Lancet. Neurology · 2025 · 46 citations · Michael Benatar